octocrylene

Small moleculeapproved

Approved

Jul 21, 2006

Octocrylene is a compound often used as an additive in sun screen, and is thought to have skin moisturizing effects because of its emollient properties. What makes this chemical such a popular additive to sun block, is its ability to neutralize UV radiation dissipated by sunlight, and to minimize skin damage from prolonged sun exposure. Octocrylene is also often combined with avobenzone, another common sunscreen ingredient often appearing on ingredient labels. Because of its effectiveness, the chemical has been approved across the globe for use in cosmetics and skin care products, but the concentrations of this ingredient are usually limited to no more than 10 or 12 percent. However, the use of this chemical doesn’t just stop with sunscreen for face and arms, but can extend to a variety of other products, like hair spray, tannin oil, BB cream, conditioner, and CC cream, among others. Octocrylene may cause contact and photocontact allergy. — NCATS

Clinical trial activity

7 trials · 8 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
2
Phase 4
1

Earliest trial started May 1, 2006 (NCT00326274)

Timeline

2000s

  1. Jan 1, 2006

    L'Oreal — Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2006

    L'Oreal — Earliest Phase 3 Sponsor(trial)

  3. Jul 21, 2006

    Earliest FDA Approval

  4. Jul 21, 2006

    L'Oreal — NDA Secondary Org

  5. Jul 21, 2006

    Sanofi-Aventis — NDA Secondary Org

  6. Oct 5, 2006

    L'Oreal — First NDA Organization

  7. Oct 5, 2006

    L'Oreal — NDA Organization

Indications

Mechanism of action

  • Unspecified targetOTHER

    Sunscreen

  • Unspecified targetUltraviolet filter

    ultraviolet filter

Combination products

Approval history

  • approvedJul 21, 2006

Chemistry & pharmacology

Loading structure…

SMILES

CCCCC(CC)COC(=O)C(C#N)=C(C1=CC=CC=C1)C2=CC=CC=C2
Mol. weight
361.4767 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Over the Counter

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • 2-ethylhexyl 2-cyano-3,3-diphenyl-2-propenoate
  • 2-ethylhexyl 2-cyano-3,3-diphenylacrylate
  • octocrilene
  • octocrilene
  • octocrilene
  • octocrylene
  • octocrylene
  • octocrylene
  • octocrylene
  • octocrylene
  • octocrylene
  • octocrylene
  • octocrylene
  • octocylene

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03012347N/AJan 1, 2017Bayer
NCT01826630N/AJul 31, 2013TopMD Skin Care, Inc.
NCT01888887N/ADec 31, 2012AMA Laboratories Inc., Galderma
NCT01695356Phase 4Sep 1, 2012Universidad Autonoma de San Luis Potosi
NCT00530387N/AJul 1, 2008University of Dundee
NCT00368563Phase 2/Phase 3 (Phase 3)Aug 1, 2006Hill Top Research, L'Oreal
NCT00326274Phase 3May 1, 2006L'Oreal
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
L'OrealFor profit2212006
AMA Laboratories Inc.For profit1012012
BayerFor profit1112017
GaldermaFor profit1112012
Hill Top ResearchFor profit1012006
TopMD Skin Care, Inc.For profit1112013
Universidad Autonoma de San Luis PotosiAcademic/Hospital1112012
University of DundeeAcademic/Hospital1112008
8 organizations
Page 1 / 1

Marketing (3)

OrganizationOrg typeRelationshipDate
L'OrealFor profitNDAOct 5, 2006
L'OrealFor profitNDA2Jul 21, 2006
Sanofi-AventisFor profitNDA2Jul 21, 2006